Step 1 topics → General Pharmacology → Heavy Metal Poisoning and Chelators

Heavy Metal Poisoning and Chelators

USMLE Step 1 trap: Applies a single chelation protocol to all lead toxicity levels, missing the level-dependent choice between oral succimer and parenteral dimercaprol/EDTA. Mild lead toxicity (blood lead 45–69 µg/dL) is treated with oral succimer (DMSA), while severe toxicity or encephalopathy (≥70 µg/dL) requires parenteral dimercaprol plus EDTA.

Heavy metal poisoning and chelation therapy is a medium-yield topic on USMLE Step 1 that shows up most often as a clinical vignette: you get a patient with a classic exposure history plus a constellation of symptoms, and you need to pick the right chelator. The exam tests this at multiple levels — pure recall (which chelator for which metal), application (which regimen based on severity), and occasionally passage interpretation where lab values guide management. The four metals you need to own are lead, arsenic, mercury, and copper (Wilson disease). Each has a distinct clinical picture, and the chelator choices have specific rules that students routinely get wrong under pressure.

The trickiest part of this topic is that students memorize one chelator per metal and stop there. That works until the exam asks *which* chelator based on blood lead level, or tests whether you know that arsenic and mercury actually share a chelator. Lead toxicity alone has two different regimens depending on severity — oral succimer for mild-to-moderate, parenteral dimercaprol plus EDTA for severe or encephalopathic cases — and collapsing those into one answer will cost you points. Wilson disease adds another layer because treatment has two phases: chelation to clear copper, then zinc acetate for maintenance. Students who only know penicillamine will miss the maintenance question every time.

USMLE Step 1 also likes to test the clinical presentations as discriminators. Lead gives you a triad of abdominal pain, neurologic symptoms (wrist/foot drop in adults, encephalopathy in kids), and anemia with basophilic stippling. Arsenic and mercury overlap significantly in presentation — both cause peripheral neuropathy and GI symptoms — which is why their shared chelator (dimercaprol/BAL, with succimer as oral alternative) makes mechanistic sense. Knowing *why* a chelator is used for a group of metals helps you reconstruct the answer even if you've blanked on pure recall.

From real student decks
68%have cards covering this topic
43%have mature cards

Common misconceptions

Common mistake
Wrong: The same chelation regimen is used regardless of blood lead level.
Right: Mild lead toxicity (blood lead 45–69 µg/dL) is treated with oral succimer (DMSA), while severe toxicity or encephalopathy (≥70 µg/dL) requires parenteral dimercaprol plus EDTA.
There is no single 'lead poisoning chelation protocol' — the regimen is explicitly severity-dependent. Blood lead 45–69 µg/dL without encephalopathy: use oral succimer (DMSA), which is safe, outpatient-compatible, and avoids the toxicity of BAL. Blood lead ≥70 µg/dL or any patient with encephalopathy: use dimercaprol (BAL) first, then add EDTA — dimercaprol goes first because EDTA alone can redistribute lead into the CNS. Memorize the cutoff of 70 µg/dL as the threshold that flips the regimen from oral to parenteral.
Common mistake
Wrong: Arsenic and mercury each require different chelating agents.
Right: Both arsenic and mercury poisoning are treated with dimercaprol (BAL) as the primary chelator, with succimer (DMSA) as an oral alternative for both.
It's tempting to assign one unique chelator per metal, but arsenic and mercury both bind sulfhydryl groups in enzymes, which is exactly what dimercaprol (BAL) was designed to protect — BAL is a dithiol compound that outcompetes the metal for those sulfhydryl sites. Because the mechanism of toxicity is the same, the antidote is the same. Succimer (DMSA) is an oral dithiol that works by the same principle and is an alternative for both. Remembering the shared mechanism (sulfhydryl inhibition → dithiol chelator) lets you reconstruct this even if the fact slips.
Common mistake
Wrong: Penicillamine is the only treatment option for Wilson disease.
Right: Penicillamine and trientine are used for initial copper chelation in Wilson disease, while zinc acetate is used for maintenance therapy by blocking intestinal copper absorption.
Penicillamine is first-line for Wilson disease and effective, but it has significant side effects (lupus-like reaction, nephrotoxicity, worsening neurologic symptoms at initiation), so trientine is the alternative chelator when penicillamine is not tolerated — both work for initial copper removal. The key concept the exam probes is *maintenance*: once copper burden is controlled, the goal shifts to preventing reabsorption, and zinc acetate does this by inducing intestinal metallothionein, which traps copper in enterocytes and blocks absorption entirely. Zinc is not a chelator and does not remove copper that's already there, so it is not interchangeable with penicillamine for initial treatment — it is specifically the maintenance agent.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a patient's blood lead level and clinical severity, identify whether oral succimer or parenteral dimercaprol plus EDTA is the appropriate chelation regimen.
  2. Recognize the classic presentation of lead poisoning — including abdominal colic, peripheral neuropathy or wrist/foot drop, anemia with basophilic stippling, and Burton lines — and distinguish it from other heavy metal toxidromes.
  3. Identify that dimercaprol (BAL) is the primary chelator shared by both arsenic and mercury poisoning, with oral succimer (DMSA) as an alternative for both.
  4. Distinguish between arsenic and mercury poisoning based on their clinical presentations, and recognize which features they share versus which are unique to each metal.
  5. In a patient with Wilson disease, identify when to use penicillamine or trientine for initial copper chelation versus zinc acetate for long-term maintenance therapy.

Can you avoid these mistakes?

A 4-year-old with pica has a blood lead level of 55 µg/dL and no neurologic symptoms. What is the appropriate chelation agent and route of administration?
A patient presents with acute GI distress, 'Mees lines' on fingernails, and a stocking-glove peripheral neuropathy after working with pesticides. Which metal is most likely responsible, and what chelator would you use? Would your chelator choice change if the metal were mercury instead?
A 22-year-old with Wilson disease has been stable on penicillamine for 2 years but develops a lupus-like reaction. You switch the chelation agent — what do you switch to? Once the disease is fully controlled, what agent would you use for long-term maintenance and why is it mechanistically different from a chelator?
On the wards, a child with lead encephalopathy arrives. Why must dimercaprol be given before EDTA in this scenario, rather than EDTA alone?

Related topics

ADME and Bioavailability Volume of Distribution (Vd) Clearance and Half-Life First-Order vs Zero-Order Elimination

See how your Anki deck covers this topic.

Upload your deck for a free audit →